Following multiple-dose administrations for 21 consecutives days of FCN-437c 200 mg once daily in female patients with ER+ and HER2- advanced breast cancer, the geometric mean Cmax,ss was 1,181 ng/mL. Here, ERBB2 is linked to breast cancer.